Blooming orchard

Targeting Disease at the Nuclear Pore
Karyopharm Therapeutics is an innovation-driven pharmaceutical company focused on the discovery, development, and commercialization of medicines with the goal of improving the lives of patients with cancer and other major diseases.

XPOVIO® (selinexor) Now Approved in New Indication

Click Here for More Information

Our Commitment to Patients

SINE Technology

Karyopharm is the industry leader in oral Selective Inhibitor of Nuclear Export (SINE) technology, developed to address a fundamental mechanism of oncogenesis.

Scientist doctor looking at sample in test tube


Our drug pipeline includes 4 unique investigational medicines targeting both hematologic malignancies and solid tumors.
Karyopharm office building


Join The Karyopharm Team

We are currently looking for candidates who share our passion to help others and who operate with a sense of urgency and a dedication to excellence.